<DOC>
	<DOCNO>NCT02422485</DOCNO>
	<brief_summary>This multi-center , open label , pilot futility clinical trial safety , tolerability , pharmacodynamics preliminary efficacy oral salsalate 10 patient PSP .</brief_summary>
	<brief_title>A 6 Month , Open-Label , Pilot Futility Clinical Trial Oral Salsalate Progressive Supranuclear Palsy</brief_title>
	<detailed_description>This multi-center , open label , pilot futility clinical trial safety , tolerability , pharmacodynamics preliminary efficacy oral salsalate 10 patient PSP . All participant administer 2,250 mg daily [ 1,500 mg every day noon ( every AM ) 750 mg every night bedtime ( every HS ) ] 6 month . If ≥3 patient experience drug limit toxicity ( DLT ) , define , study terminate . A DLT define : 1 ) Grade 3 high adverse event ( AE ) per National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) reasonable possibility salsalate cause event , 2 ) Grade 2 AE CTCAE system organ class nervous system disorder consider clinically significant reasonable possibility salsalate cause event , 3 ) Grade 2 high treatment-related adverse event administration resolve promptly supportive treatment . An interim futility analysis perform five subject complete 6 month study drug treatment . If criterion list Statistical Methods section synopsis meet , additional 5 subject enrol trial . If , trial terminate .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Salicylsalicylic acid</mesh_term>
	<mesh_term>Sodium Salicylate</mesh_term>
	<criteria>1 . Meets National Institute Neurological Disorders Stroke Society Progressive Supranuclear Palsy ( NINDSSPSP ) probable possible PSP criterion , ( Litvan 1996a ) modify AL108231 trial . ( Boxer 2014 ) 2 . Aged 5085 3 . Agrees 3 magnetic resonance imaging ( MRI ) subject investigator 's discretion 4 . MRI screen consistent PSP ( ≤4 microhemorrhages large stroke severe white matter disease ) 5 . MiniMental State Examination ( MMSE ) score 1430 6 . Stable medication 2 month prior screen , include FDA approve Alzheimer 's disease ( AD ) medication Parkinson 's disease medication 7 . Availability study partner know patient well willing accompany patient trial visit participate questionnaire 8 . Agrees 2 lumbar puncture cerebrospinal fluid ( CSF ) examination 9 . Signed date write informed consent obtain subject subject 's caregiver accordance local IRB regulation 10 . Males WCBP agree abstain sex use adequate method contraception duration study 30 day last dose study drug . Adequate contraceptive method include low failure rate , i.e. , less 1 % per year , use consistently correctly , complete abstinence sexual intercourse potentially fertile partner , double barrier method condom spermicide ) conjunction use partner intrauterine device ( IUD ) , diaphragm spermicide , oral contraceptive , birth control patch vaginal ring , oral , injectable implanted contraceptive . For study , woman surgically sterilize state amenorrhea two year deem childbearing potential ; 1 . Meets National Institute AgingAlzheimer 's Association Workgroups criterion probable AD ( McKhann et al . 2011 ) ; 2 . Any medical condition PSP could account cognitive deficit ( e.g. , active seizure disorder , stroke , vascular dementia ) ; 3 . A prominent sustain response levodopa therapy ; 4 . History significant cardiovascular , hematologic , renal , hepatic disease ( laboratory evidence thereof ) ; 5 . History hypertension ( repeat elevation blood pressure exceed 180 mm Hg systolic 100 mm Hg diastolic ; medical intervention indicate ) ; 6 . History severe gastrointestinal bleed , gastric peptic ulcer ; 7 . History aspirin triad ( i.e. , aspirin allergy , nasal polyp asthma ) asthma ; 8 . History major psychiatric illness untreated depression ; 9 . Neutrophil count &lt; 1,500/mm3 , platelet &lt; 100,000/mm3 , serum creatinine &gt; 1.5 x upper limit normal ( ULN ) , total bilirubin &gt; 1.5 x ULN , alanine aminotransferase ( ALT ) &gt; 3 x ULN , aspartate aminotransferase ( AST ) &gt; 3 x ULN , INR &gt; 1.2 Screening evaluation ; 10 . Evidence clinically significant finding Screening baseline evaluation , opinion Investigator would pose safety risk interfere appropriate interpretation study data ; 11 . Current recent history ( within four week prior Screening ) clinically significant bacterial , fungal , mycobacterial infection ; 12 . Current clinically significant viral infection . Subjects chicken pox , influenza , flu symptom eligible ; 13 . Major surgery within four week prior Screening ; 14 . Any contraindication unable tolerate lumbar puncture Screening , include use anticoagulant medication warfarin . Daily administration 81 mg aspirin allow long dose stable 30 day prior Screening ; 15 . Treatment another investigational drug participation another interventional clinical trial within 3 month Screening ; 16 . Chronic use NSAIDs salicylates reason , except daily baby aspirin ( 81 mg ) ; 17 . Concurrent treatment thiazide loop diuretic ; 18 . Concurrent use oral corticosteroid angiotensinconverting enzyme ( ACE ) inhibitor ; 19 . Treatment human blood product , include intravenous immunoglobulin , 6 month prior Screening trial ; 20 . Known hypersensitivity inactive ingredient study drug ; 21 . Pregnant lactating ; 22 . Positive pregnancy test Screening Baseline ( Day 1 ) ; 23 . Cancer within 5 year Screening , except nonmetastatic skin cancer nonmetastatic prostate cancer expect cause significant morbidity mortality within one year Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Salsalate</keyword>
</DOC>